Introduction/Background Borderline ovarian tumors are diagnosed in younger patients and at earlier stages. Our aim in our study was to evaluate the preoperative conditions, treatments and post operative conditions of patients treated in our university hospital.

Methodology From the hospital databases, patient age, menopausal status, preoperative tumor markers, and preoperative ultrasound characteristics were collected. After up front surgery, the surgical technique, histological type, stage at diagnosis, tumor diameter, lymph node status, final pathological diagnosis were also collected. Additionally, adjuvant treatments, postoperative follow up periods, and possible recurrences were evaluated.

Results This study includes 80 patients who were operated between 2007–2022. Median age of our study groups was 42,2 (15–88). 57 (71,3%) of patients was premenopausal. Malignant tumor was detected in the final pathology in 10 (12,5%) patients. Six of these patients had serous tumors and 4 had mucinous tumors. Disease recurrence was detected in 3 (3,8%) patients, the mean progression free survival of these patients was 19 months. All patients with recurrence were in the early stage and 2 had micropapillary variant. And recurrence was detected in the contralateral ovary in one of the patients who relapsed after oophorectomy and the others after cystectomy. Micropapillary variant and cyctectomy had been identified as the most important risk factors for disease recurrence. Histopathological subtypes of recurrences were included serous and mucinous borderline tumors.

Conclusion In conclusion, micropapillary variant and cyctectomy is the most important risk factors for disease recurrence. Routine lymph node dissection or sampling, appendectomy or hysterectomy did not cause any difference in terms of recurrence. Our findings suggest that comprehensive surgical staging or radical surgical approaches should not be performed in borderline ovarian tumor. Cystectomy can be used to preserve fertility, but it should be noted that this increases the risk of disease recurrence.

Disclosures none